(Total Views: 803)
Posted On: 03/31/2020 10:55:29 AM
Post# of 148870
Finally.... something on PR Newswire:
https://www.prnewswire.com/news-releases/over...32608.html
May not be much to us who know but think the world will now get to know.
https://www.prnewswire.com/news-releases/over...32608.html
Quote:
CytoDyn Inc. (OTCQB: CYDY) recently announced that an additional three critically ill COVID-19 patients have been treated with leronlimab. These additional patients increase the total to 10 patients receiving leronlimab treatment under an Emergency Investigational New Drug (EIND) granted by the U.S. Food and Drug Administration (FDA).
The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19). Leronlimab is believed to provide therapeutic benefit by enhancing the immune response while mitigating the "cytokine storm" that leads to morbidity and mortality in these patients. The laboratory evaluation of the first four patients treated with leronlimab revealed that the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm (including IL-6 and TNF alpha) were much improved. The results of the three additional patients are expected this week.
May not be much to us who know but think the world will now get to know.
(2)
(0)Scroll down for more posts ▼
